{"id":"NCT02720198","sponsor":"Duke University","briefTitle":"Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD","officialTitle":"A Randomized Trial Comparing Efficacy and Tolerability of Levomilnacipran Switch Versus Adjunctive Quetiapine in Major Depressive Disorder (MDD) With Inadequate Response to SSRIs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-23","primaryCompletion":"2018-06-12","completion":"2018-06-12","firstPosted":"2016-03-25","resultsPosted":"2019-07-02","lastUpdate":"2019-08-14"},"enrollment":60,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Levomilnacipran","otherNames":["Fetzima"]},{"type":"DRUG","name":"Quetiapine","otherNames":["Seroquel"]}],"arms":[{"label":"Levomilnacipran","type":"ACTIVE_COMPARATOR"},{"label":"Quetiapine","type":"ACTIVE_COMPARATOR"}],"summary":"This study's primary objective is to compare the efficacy and tolerability of switching patients with inadequate relief on generic SSRIs to levomilnacipran versus adding a new treatment (quetiapine) to the participants' existing treatment with people diagnosed with depression (major depression disorder).\n\nThe secondary objective is to examine the response and remission rates following the switch from a generic SSRI to levomilnacipran ER and augmentation with quetiapine along with examining changes in neurocognitive and apathy measures after the switch.","primaryOutcome":{"measure":"Changes of Montgomery-Ã…sberg Depression Rating Scale (MADRS) Total Score","timeFrame":"Baseline to Week 8","effectByArm":[{"arm":"Levomilnacipran","deltaMin":-5.81,"sd":6.08},{"arm":"Quetiapine","deltaMin":-6.97,"sd":7.632}],"pValues":[{"comp":"OG000 vs OG001","p":"0.53"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":21},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":29},"commonTop":["Drowsiness","Nausea","Headache","Weight Gain","Increase Appetite"]}}